Evidence map›Paper›PMID 33595761›Full record

ArticleCardiovascular drugs and therapy2022

Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19.

Laurent Chouchana, Nathanaël Beeker, Nicolas Garcelon, Bastien Rance, Nicolas Paris, Elisa Salamanca, Elisabeth Polard, Anita Burgun, Jean-Marc Treluyer, Antoine Neuraz and 1 more

Erratum issuedOpen access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular drugs and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Observational
  7. Review
  8. Observational
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Laurent ChouchanaCentre Régional de Pharmacovigilance, Département de Pharmacologie, Hôpital Cochin, AP-HP.Centre - Université de Paris, 27 rue du Faubourg Saint-Jacques, 75014, Paris, France. laurent.chouchana@aphp.fr.ORCID 0000-0002-9626-3571
Nathanaël BeekerUnité de Recherche clinique, Hôpital Cochin, AP-HP.Centre - Université de Paris, Paris, France.
Nicolas GarcelonCentre de Recherche des Cordeliers, INSERM UMRS_1138 Team 22, Université de Paris, Paris, France.
Bastien RanceCentre de Recherche des Cordeliers, INSERM UMRS_1138 Team 22, Université de Paris, Paris, France.
Nicolas ParisDépartement Web Innovation Données (WIND), Direction des systèmes d'information, AP-HP, Paris, France.
Elisa SalamancaDépartement Web Innovation Données (WIND), Direction des systèmes d'information, AP-HP, Paris, France.
Elisabeth PolardCentre Régional de Pharmacovigilance, pharmacoépidémiologie et information sur le médicament, CHU Rennes, Rennes, France.
Anita BurgunCentre de Recherche des Cordeliers, INSERM UMRS_1138 Team 22, Université de Paris, Paris, France.
Jean-Marc TreluyerCentre Régional de Pharmacovigilance, Département de Pharmacologie, Hôpital Cochin, AP-HP.Centre - Université de Paris, 27 rue du Faubourg Saint-Jacques, 75014, Paris, France.
Antoine NeurazCentre de Recherche des Cordeliers, INSERM UMRS_1138 Team 22, Université de Paris, Paris, France.
AP-HP/Universities/Inserm COVID-19 research collaboration, AP-HP Covid CDR Initiative, and “Entrepôt de Données de Santé” AP-HP Consortium”
Assistance Publique – Hôpitaux de Paris · FRHôpital Necker-Enfants Malades · FRInserm · FRUniversité Paris Cité · FRCentre de Recherche des Cordeliers · FRHôpital Cochin · FRLaboratoire de Biophotonique et Pharmacologie · FR

Funding

Agence Nationale de la Recherche ANR-10-IAHU-01Agence Nationale de la Recherche ANR-15-CE23-0028
6 · The paper itself

Abstract

purposeThe role of angiotensin receptor blockers (ARB), angiotensin-converting enzyme inhibitors (ACEi), or other antihypertensive agents in the case of Covid-19 remains controversial. We aimed to investigate the association between antihypertensive agent exposure and in-hospital mortality in patients with Covid-19.

methodsWe performed a retrospective multicenter cohort study on patients hospitalized between February 1 and May 15, 2020. All patients had been followed up for at least 30 days.

resultsOf the 8078 hospitalized patients for Covid-19, 3686 (45.6%) had hypertension and were included in the study. In this population, the median age was 75.4 (IQR, 21.5) years and 57.1% were male. Overall in-hospital 30-day mortality was 23.1%. The main antihypertensive pharmacological classes used were calcium channel blockers (CCB) (n=1624, 44.1%), beta-blockers (n=1389, 37.7%), ARB (n=1154, 31.3%), and ACEi (n=998, 27.1%). The risk of mortality was lower in CCB (aOR, 0.83 [0.70-0.99]) and beta-blockers (aOR, 0.80 [0.67-0.95]) users and non-significant in ARB (aOR, 0.88 [0.72-1.06]) and ACEi (aOR, 0.83 [0.68-1.02]) users, compared to non-users. These results remain consistent for patients receiving CCB, beta-blocker, or ARB as monotherapies.

conclusionThis large multicenter retrospective of Covid-19 patients with hypertension found a reduced mortality among CCB and beta-blockers users, suggesting a putative protective effect. Our findings did not show any association between the use of renin-angiotensin-aldosterone system inhibitors and the risk of in-hospital death. Although they need to be confirmed in further studies, these results support the continuation of antihypertensive agents in patients with Covid-19, in line with the current guidelines.

Indexed as

COVID-19HypertensionAdrenergic beta-AntagonistsAgedAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAntihypertensive AgentsCalcium Channel BlockersCohort StudiesFemaleHospital MortalityHumansMaleRetrospective StudiesAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAntihypertensive AgentsCalcium Channel BlockersCalcium channel blockersCovid-19Drug safetyHypertensionRenin-angiotensin-aldosterone inhibitorsSARS-CoV-2

Identifiers

PMID33595761
PMCPMC7887412
OpenAlexW3132855917

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.